Vetr cut shares of Celgene Co. (NASDAQ:CELG) from a strong-buy rating to a buy rating in a research report report published on Thursday, May 11th. They currently have $132.90 price objective on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently issued reports on CELG. Robert W. Baird restated an outperform rating and set a $162.00 target price on shares of Celgene in a report on Wednesday, January 11th. Cowen and Company reiterated an outperform rating and set a $150.00 price objective on shares of Celgene in a report on Thursday, January 12th. Zacks Investment Research upgraded Celgene from a sell rating to a hold rating in a report on Friday, January 13th. Cantor Fitzgerald set a $159.00 target price on Celgene and gave the company a buy rating in a research note on Friday, January 13th. Finally, Cann restated a buy rating on shares of Celgene in a research note on Thursday, January 26th. One research analyst has rated the stock with a sell rating, six have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $139.05.
Shares of Celgene (NASDAQ CELG) opened at 118.10 on Thursday. The company’s 50-day moving average is $120.30 and its 200 day moving average is $119.75. The stock has a market cap of $92.22 billion, a PE ratio of 44.35 and a beta of 1.74. Celgene has a 52 week low of $94.42 and a 52 week high of $127.64.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.21. Celgene had a return on equity of 77.95% and a net margin of 17.80%. The firm had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3.04 billion. During the same period last year, the company earned $1.32 earnings per share. The company’s revenue was up 17.8% on a year-over-year basis. Analysts forecast that Celgene will post $7.29 earnings per share for the current fiscal year.
WARNING: “Celgene Co. (CELG) Downgraded by Vetr Inc.” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/06/06/celgene-co-celg-lowered-to-buy-at-vetr-inc-updated-updated.html.
In related news, Director James J. Loughlin sold 9,250 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $124.00, for a total value of $1,147,000.00. Following the transaction, the director now directly owns 32,169 shares of the company’s stock, valued at approximately $3,988,956. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 14,033 shares of the company’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $123.83, for a total value of $1,737,706.39. Following the completion of the transaction, the director now directly owns 73,109 shares in the company, valued at $9,053,087.47. The disclosure for this sale can be found here. Corporate insiders own 0.97% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in CELG. Motco boosted its position in Celgene by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Celgene during the first quarter valued at $118,000. Carroll Financial Associates Inc. boosted its position in Celgene by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares during the last quarter. FNY Managed Accounts LLC purchased a new position in Celgene during the first quarter valued at $131,000. Finally, Oakworth Capital Inc. boosted its position in Celgene by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares during the last quarter. 77.68% of the stock is currently owned by hedge funds and other institutional investors.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
To view Vetr’s full report, visit Vetr’s official website.
What are top analysts saying about Celgene Co.? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for Celgene Co. and related companies.